AB 423

Drug Profile

AB 423

Alternative Names: AB-423

Latest Information Update: 19 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Baruch S. Blumberg Institute; Drexel University College of Medicine
  • Developer Arbutus Biopharma
  • Class Antivirals; Bacteriophages; Small molecules
  • Mechanism of Action Capsid protein inhibitors; Hepatitis B virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hepatitis B

Most Recent Events

  • 14 Mar 2018 Arbutus Biopharma completes a phase I trial in Hepatitis B (In healthy volunteers) in Canada (PO)
  • 24 Oct 2017 Interim pharmacokinetics and adverse events data from a phase I trial in Healthy volunteers released by Arbutus Biopharma
  • 20 Oct 2017 Updated pharmacokinetics and adverse events data from a phase I trial in Healthy volunteers presented at the 68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top